Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

July 31, 2006

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

rabeprazole sodium

administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.

Trial Locations (25)

11501

Winthrop University Hospital, Mineola

14222

Children's Hospital of Buffalo - Digestive Disease And Nutrition Center, Buffalo

17257

Biomedical Research Associates, Shippensburg

25701

Marshall University, Huntington

29651

DeGarmo Institute of Medicine Research, Greer

30039

Dr. Patricia Barrington, Dr. B. Abraham, PC, Snellville

33328

Nova Southeastern University, Fort Lauderdale

34652

Babies and Beyond Peds, New Port Richey

37075

Focus Research Group, Hendersonville

37087

NE Ohio University College of Medicine, Lebanon

37601

ProMed Healthcare, Johnson City

40004

Kentucky Pediatric/Adult Research, Bardstown

43701

Pharmacotherapy Research Associates, Zanesville

44514

Center for Children's Digestive Health, Youngstown

45040

University of Pediatrics, Mason

45245

Pediatric Associates of Mount Carmel, Inc., Cincinnati

Pediatric Associates of Mt. Carmel, Cincinnati

49008

Community Pediatric Associates, Kalamazoo

49601

Professional Clinical Research, Cadillac

60194

Multi-specialty Clinical Research, Hoffman Estates

68105

The Center for Human Nutrition, Omaha

78229

Southwest Children's Research Associates, San Antonio

80501

Longmont Medical Research Network, Longmont

84102

Alpine Medical Group, Salt Lake City

99202

Rockwood Clinic North, Spokane

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00132496 - Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole | Biotech Hunter | Biotech Hunter